Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia

Human Psychopharmacology

Volumn 28, Issue 2, 2013, Pages 124-133

  Egan, Michael F ^a   Zhao, Xin ^a   Smith, Andrew ^a   Troyer, Matthew D ^a   Uebele, Victor N ^a   Pidkorytov, Valerii ^b   Cox, Kevin ^c   Murphy, Michael ^d   Snavely, Duane ^a   Lines, Christopher ^a   Michelson, David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^c Worldwide Clinical Trials   (United States)

^d Worldwide Clinical Trials   (United States)

Author keywords

MK 8998; olanzapine; randomized trial; schizophrenia; T type calcium channel antagonist

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; MK 8998; OLANZAPINE; PLACEBO; UNCLASSIFIED DRUG;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ACUTE PSYCHOSIS; ADULT; ARTICLE; BARNES AKATHISIA SCALE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYSIPELAS; ERYTHROCYTE COUNT; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE CONDUCTION; HEMATOCRIT; HUMAN; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MORNING DOSAGE; MULTICENTER STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; TONIC CLONIC SEIZURE; VITAL SIGN; WEAKNESS;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84875671353     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2289     Document Type: Article

References (31)

1. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders. Fourth ed., Text Revision. American Psychiatric Association: Washington, D.C.
2. Barnes TRE,. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
3. Barnes TRE,. 2003. The Barnes Akathisia Rating Scale-revisited. J Psychopharmacol 17: 365-370.
4. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S,. 1996a. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 124: 159-167.
5. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S,. 1996b. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14: 111-123.
6. Choi KH, Rhim H,. 2010. Inhibition of recombinant Ca(v)3.1 (alpha(1 G)) T-type calcium channels by the antipsychotic drug clozapine. Eur J Pharmacol 626: 123-130.
7. Cutler NR,. 2001. Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. J Clin Psychiatry 62 (Suppl 5): 10-13.
8. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S., 2005. Olanzapine for schizophrenia. Cochrane Database Syst. Rev. (2), CD001359.
9. Enyeart JJ, Biagi BA, Mlinar B,. 1992. Preferential block of T-type calcium channels by neuroleptics in neural crest-derived rat and human C cell lines. Mol Pharmacol 42: 364-372.
10. Guy W., 1976. EDCEU Assessment Manual for Psychopharmacology-Revised. U.S. Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, second ed., NIMH, Rockville, MD. pp. 218-222. DHEW Publ. No. ADM 76-338.
11. Huc S, Monteil A, Bidaud I, Barbara G, Chemin J, Lory P,. 2009. Regulation of T-type calcium channels: signaling pathways and functional implications. Biochim Biophys Acta 1793: 947-952.
12. Kane JM, Correll CU,. 2010. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci 12: 345-357.
13. Kay SR, Opler LA, Fiszbein A,. 1994. Positive and Negative Syndrome Scale Manual. Multi-Health Systems: North Tonawanda, NY.
14. Kemp AS, Schooler NR, Kalali AH, et al,. 2010. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull 36: 504-509.
15. Kraus RL, Li Y, Gregan Y, et al,. 2010. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J. Pharm. Exp. Therap. 335: 409-417.
16. Kumar R, Sachdev PS,. 2009. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry 22: 293-299.
17. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis J.M., 2009. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31-41.
18. Liang K, Zeger S., 2000. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhyā: The Indian Journal of Statistics 62 (Series B): 134-148.
19. Lieberman JA, Stroup TS, McEvoy JP, et al,. 2005. Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
20. Liu GF, Lu K, Mogg R, Mallick M, Mehrotra DV,. 2009. Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials? Stat Med 28: 2509-2530.
21. Llinas RR, Ribary U, Jeanmonod D, Kronberg E, Mitra PP,. 1999. Thalamocortical dysrhythmia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography. Proc Natl Acad Sci (USA) 96: 15222-15227.
22. Matza LS, Baker TM, Revicki DA,. 2005. Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review. CNS Drugs 19: 499-515.
23. Montgomery SA, Asberg M,. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
24. Munetz MR, Benjamin S,. 1988. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp. Community Psychiatry 39: 1172-1177.
25. Patil ST, Zhang L, Martenyi F, et al,. 2007. Activation of mGlu2/3receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13: 1102-1107.
26. Santi CM, Cayabyab FS, Sutton KG, et al,. 2002. Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci 22: 396-403.
27. Simpson GM, Angus JWS,. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavia Suppl. 212: 11-19.
28. Uebele VN, Gotter AL, Nuss CE, et al,. 2009. Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice. J Clin Invest 119: 1659-1667.
29. Uslaner JM, Smith SM, Huszar SL, et al,. 2012. T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats. Neuropharmacology 62: 1413-1421.
30. Yang ZQ, Barrow JC, Shipe WD, et al,. 2008. Discovery of 1,4-Substituted piperidines as potent and selective inhibitors of T-type calcium channels. J Med Chem 51: 6471-6477.
31. Zhang Y, Llinas RR, Lisman JE,. 2009. Inhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting. Fron.Neur. Circuits 3: 20.